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Letters to the Editor
Platelet Aspirin
Resistance Detection and Validation
In a recent paper in the Journal, Tantry et al. (1) concluded that the
occurrence of aspirin resistance in published reports is overesti-
mated, implying that this was due to the use of assays that did not
measure cyclooxygenase-1 (COX-1) activity. Although these in-
vestigators reported an incidence of aspirin resistance of 0.4%,
several reviews estimate, based on a large number of studies, that
the incidence of aspirin resistance is between 5% and 45% (2).
Moreover, the Tantry et al. (1) study has serious limitations that
call into question the generalizability of their findings.
First, their research population consisted primarily of patients
with stable angina. A number of studies have demonstrated that
aspirin resistance is more prevalent in patients with acute coronary
syndromes than in patients with stable angina (2), and thus their
study may underestimate the prevalence of aspirin resistance in
those at greatest risk. Second, by employing a dose of 325 mg of
aspirin, their data may not be applicable to the vast majority of
patients who currently are treated with 81 mg per day. Third,
because their definition of aspirin resistance has not been validated
against clinical outcomes, it is arbitrary and thus must be viewed as
speculative. Fourth, the thrombelastograph (TEG) assay they use
has not undergone extensive critical evaluation.
Tantry et al. (1) also do not accurately portray the VerifyNow–
ASA System (Ultegra System, Accumetrics, San Diego, California),
which employs arachidonic acid (AA) as the agonist and thus does
assess COX-1 activity. When compared to light transmission aggre-
gometry (LTA) using AA, the VerifyNow assay demonstrated
91.4% sensitivity and 100% specificity (VerifyNow–ASA package
insert). Although a previous generation of the VerifyNow device
did use propyl gallate (PG) as the agonist, Schwartz et al. (3)
demonstrated that PG detects aspirin-induced inhibition of plate-
lets with 100% sensitivity and differentiates the degree of aspirin-
induced inhibition of platelet function produced by single doses of
81 mg and 325 mg, and hence is a specific activator of the
aspirin-inhibited COX-1 pathway. Most importantly, results of
the VerifyNow assay have been correlated to clinical outcome in
several studies, including one published in JACC (4–6).
Several studies, including a recent one by Lee et al. (7) with
VerifyNow, have demonstrated that aspirin resistance decreases
with increasing dose of aspirin, from 81 mg to 325 mg. Maree
et al. (8) also demonstrated using AA-induced LTA as well as
serum thromboxane measurements, the gold standard, that “many
patients who are prescribed low-dose aspirin (81 mg) have persis-
tent uninhibited platelet COX activity.” Further, Serebruany et al.
(9) have shown that major bleeding increases from 1% to 3% as
aspirin dose is increased from 81 mg to 325 mg Thus, there is a
graded effect in both safety and efficacy of aspirin that should be
considered.
Noncompliance and drug interactions with nonsteroidal anti-
inflammatory drugs (e.g., ibuprofen) contribute to the reported
incidence of “aspirin resistance” in the real world of clinical
practice, and many investigators, including Cotter et al. (10),
conclude that “nonadherence is a significant mediator of poor
outcome . . . and it is important to evaluate whether or not patients
are taking their medications in clinical settings.” Thus, assays that
ensure an antiplatelet effect may have great clinical value even in
patient populations in whom, as reported by Tantry et al. (1),
biochemical aspirin resistance is uncommon.
As stated by Schneider (11) in an accompanying editorial, initial
techniques used to assess the effect of glycoprotein IIb/IIIa
inhibitors on platelet function were inadequate. The original
VerifyNow IIb/IIIa assay was used in the AU-Assessing Ultegra
(GOLD) study (12), which served to definitively establish the
correlation between platelet inhibition and clinical outcomes.
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REPLY
We appreciate Dr. Hillman’s interest in our study assessing
cyclooxygenase (COX)-1 inhibition by stimulation of platelets
with arachidonic acid (AA) in platelet-rich plasma and whole
blood. We address his comments:
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1. The AA-induced aggregation measured by light transmission
aggregometry (LTA) is the most widely reported ex vivo
technique to assess aspirin effect in platelets (1–3). With
respect to our study potentially underestimating aspirin resis-
tance in patients with unstable coronary syndromes, it should
be noted that 23% (n  47) of our percutaneous coronary
intervention (PCI) patients were in that category. All of these
patients were sensitive to aspirin (4). To the best of our
knowledge, our prospective study is the largest reported in PCI
patients and is concordant with Schwartz et al (5), who
reported 1 of 190 patients resistant to aspirin using 1 mol/l
arachidonic acid (AA)-induced aggregation in platelet-rich
plasma. The latter investigators also reported that 9% of
patients exhibiting “resistance” were proven to be responders
after strict adherence to aspirin treatment. These data are
strikingly consistent with the results of our study (4).
2. Controversy remains regarding dose-dependent effects of as-
pirin on ex vivo platelet function. The latter effects may be
COX-1 independent. We are currently conducting a double
crossover study in outpatients that addresses these important
issues.
3. With respect to the relation of ex vivo AA-induced aggrega-
tion to clinical outcomes, the single patient who was aspirin-
resistant in our study had suffered a stent thrombosis. We
agree that large-scale studies are necessary to firmly link ex vivo
platelet function measurements to the occurrence of adverse
ischemic events.
4. With respect to the assertion that the thrombelastograph
(TEG) assay has not undergone extensive evaluation, it should
be noted that the TEG platelet mapping assay has been cleared
by the Food and Drug Administration as an automated platelet
aggregation system. As reported in our study, a statistically
significant correlation existed between measurements by LTA
and TEG (r 0.85; p 0.001). We are currently studying the
relation of TEG measurements to the occurrence of recurrent
ischemic events (6). The TEG has been used for many years to
guide therapy in patients with postsurgical bleeding.
5. We referred to a previous study of the VerifyNow assay
using propyl gallate (PG) as the agonist (7). There are no
published data correlating PG as an agonist to AA in the
measurement of aspirin resistance. At the time we submit-
ted our findings to JACC, PG was the only reported agonist
used in the VerifyNow assay to assess platelet responsive-
ness to aspirin. Moreover, no major studies describing the
new AA cartridge in the VerifyNow assay had occurred
prior to, and none have occurred since, our submission to
JACC.
6. The relation of aspirin dose to bleeding remains controversial.
We believe that this subject would be best addressed by
prospective studies and not by meta-analyses.
7. We agree that there is much confusion regarding aspirin
“resistance,” and this was indeed the stimulus to conduct our
investigation. Stimulation by multiple pathways will affect
measurements of ex vivo platelet function and the interpreta-
tion of drug “resistance.” A technique that isolates the specific
pathway targeted by the drug should be used to assess drug
response. Therefore, we believe that failure to inhibit the
primary target of aspirin (i.e., COX-1) should be the criterion
for aspirin resistance. The primary message of our study was
that the prevalence of aspirin resistance using this definition is
rare after treatment with a 325-mg daily dose.
Finally, we emphasize that aspirin resistance may be an impor-
tant phenomenon related to the occurrence of adverse clinical
events. A standardized definition that will employ validated
point-of-care methods to facilitate investigations in large-scale
clinical trials is needed. A critical assessment of pathways affected
by aspirin will also determine whether clinical events are only
related to incomplete platelet COX-1 inhibition or to other
anti-inflammatory or antioxidant properties of aspirin that may be
dose-dependent.
Udaya S. Tantry, PhD
Kevin P. Bliden, BS
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Bifurcation Coronary
Lesions and the “Crush” Technique
We read with interest the study by Costa et al. (1) clarifying a
number of important aspects of the treatment of bifurcation lesions
by the crush technique. The investigators reported that “the
majority of SB (side branch) lesions showed stent underexpansion
with the smallest MSA (mean sent area) found at the SB ostium,”
and that this underexpansion was not reliably detected by angi-
ography. Given the potential implications of these findings on the
development of both stent thrombosis and restenosis at the ostium
of the SB, it would be interesting to know additional details on
how the crush technique was performed in this study. Bench-
testing has demonstrated procedural issues that maximize the
likelihood of adequate dilation of the SB ostium, including
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